Morgan Stanley: Give WuXi Biologics an "overweight" rating, and the target price rose by 3.6% to HK $170
智通财经2021-08-26
Morgan Stanley released a research report saying that
WuXi Biologics(02269) "overweight" rating, the target price was raised from HK $164 to HK $170, and the profit forecast for 2021-24 was raised by 1% to 9% to reflect the strong performance in the first half of the year, and the revenue and gross profit forecasts were also raised simultaneously.
followStraight flushFinance (ths518), access more opportunities
Editor in charge: cjh
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
